Dong-A ST Zukünftiges Wachstum

Future Kriterienprüfungen 3/6

Dong-A ST wird ein jährliches Gewinn- und Umsatzwachstum von 65.2% bzw. 2.6% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 65.9% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 5.8% betragen.

Wichtige Informationen

65.3%

Wachstumsrate der Gewinne

66.1%

EPS-Wachstumsrate

Pharmaceuticals Gewinnwachstum	36.0%
Wachstumsrate der Einnahmen	2.8%
Zukünftige Eigenkapitalrendite	5.9%
Analystenabdeckung	Low
Zuletzt aktualisiert	24 Jun 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Dong-A ST's (KRX:170900) Shareholders Have More To Worry About Than Only Soft Earnings

Mar 25

Dong-A ST Co., Ltd. (KRX:170900) Stock Rockets 27% As Investors Are Less Pessimistic Than Expected

Mar 07

Is Dong-A ST Co., Ltd.'s (KRX:170900) Stock's Recent Performance A Reflection Of Its Financial Health?

Feb 09

Is Dong-A ST Co., Ltd. (KRX:170900) Popular Amongst Institutions?

Jan 25

Is Dong-A ST Co., Ltd. (KRX:170900) A Good Fit For Your Dividend Portfolio?

Jan 11

Be Sure To Check Out Dong-A ST Co., Ltd. (KRX:170900) Before It Goes Ex-Dividend

Dec 25

Dong-A ST (KRX:170900) Has A Rock Solid Balance Sheet

Dec 22

Calculating The Intrinsic Value Of Dong-A ST Co., Ltd. (KRX:170900)

Dec 07

A Look At Dong-A ST's (KRX:170900) Share Price Returns

Nov 19

Gewinn- und Umsatzwachstumsprognosen

KOSE:A170900 - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (KRW Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	741,400	63,000	80,000	70,000	2
12/31/2025	683,940	37,825	46,767	57,640	5
12/31/2024	660,300	39,800	65,000	19,100	1
3/31/2024	672,231	-5,182	-50,385	-9,557	N/A
12/31/2023	663,980	11,122	-38,489	3,374	N/A
9/30/2023	637,080	5,289	-56,043	-9,441	N/A
6/30/2023	632,152	18,314	-32,755	15,843	N/A
3/31/2023	626,247	19,507	-56,251	3,549	N/A
12/31/2022	635,393	13,552	-33,653	32,895	N/A
9/30/2022	634,156	20,490	-32,798	51,531	N/A
6/30/2022	624,348	10,545	-41,970	46,424	N/A
3/31/2022	608,566	13,792	-24,770	61,727	N/A
12/31/2021	593,228	12,816	-31,066	49,374	N/A
9/30/2021	568,502	4,029	-28,714	37,764	N/A
6/30/2021	562,255	-3,362	-32,402	29,698	N/A
3/31/2021	526,362	-18,566	-32,629	16,974	N/A
12/31/2020	586,728	27,103	-14,916	27,031	N/A
9/30/2020	614,778	64,631	14,983	46,006	N/A
6/30/2020	630,909	80,237	45,142	64,313	N/A
3/31/2020	670,903	97,181	47,835	64,399	N/A
12/31/2019	612,311	70,913	37,509	56,254	N/A
9/30/2019	594,546	21,310	46,231	64,385	N/A
6/30/2019	573,442	7,015	22,026	37,878	N/A
3/31/2019	574,391	20,620	41,189	55,250	N/A
12/31/2018	567,434	8,009	41,457	50,136	N/A
9/30/2018	574,260	24,985	39,569	47,442	N/A
6/30/2018	577,496	30,598	33,200	42,154	N/A
3/31/2018	557,657	13,574	18,679	28,967	N/A
12/31/2017	555,027	-5,396	N/A	51,233	N/A
9/30/2017	534,096	13,724	N/A	40,602	N/A
6/30/2017	526,621	-4,703	N/A	47,631	N/A
3/31/2017	546,731	-13,140	N/A	13,167	N/A
12/31/2016	560,535	2,623	N/A	1,890	N/A
9/30/2016	576,257	9,384	N/A	2,383	N/A
6/30/2016	588,973	27,434	N/A	5,928	N/A
3/31/2016	572,577	43,069	N/A	49,091	N/A
12/31/2015	567,940	47,495	N/A	42,397	N/A
9/30/2015	573,434	42,755	N/A	54,475	N/A
6/30/2015	560,372	42,855	N/A	70,798	N/A
3/31/2015	574,235	37,791	N/A	72,214	N/A
12/31/2014	578,640	37,412	N/A	84,746	N/A
9/30/2014	685,763	24,320	N/A	72,487	N/A
6/30/2014	703,607	20,485	N/A	64,126	N/A
12/31/2013	601,161	-78,858	N/A	-17,063	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: A170900 wird in den nächsten 3 Jahren voraussichtlich rentabel werden, was als schnelleres Wachstum als die Sparquote angesehen wird (2.5%).

Ertrag vs. Markt: A170900 wird in den nächsten 3 Jahren voraussichtlich rentabel werden, was als überdurchschnittliches Marktwachstum angesehen wird.

Hohe Wachstumserträge: A170900 wird voraussichtlich in den nächsten 3 Jahren rentabel werden.

Einnahmen vs. Markt: A170900Die Einnahmen des Unternehmens (2.6% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt KR (10.2% pro Jahr).

Hohe Wachstumseinnahmen: A170900Die Einnahmen des Unternehmens (2.6% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: A170900Die Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich niedrig sein (5.8 %).

Dong-A ST Zukünftiges Wachstum

Future Kriterienprüfungen 3/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Price target increased by 7.6% to ₩77,624

Price target decreased to ₩77,200

Price target decreased to ₩95,667

Price target decreased to ₩105,000

Recent updates

Less than half of directors are independent

Dong-A ST Co., Ltd. to Report Q1, 2024 Results on May 02, 2024

Dong-A ST's (KRX:170900) Shareholders Have More To Worry About Than Only Soft Earnings

Full year 2023 earnings released: EPS: ₩1,311 (vs ₩1,606 in FY 2022)

Dong-A ST Co., Ltd. (KRX:170900) Stock Rockets 27% As Investors Are Less Pessimistic Than Expected

Dong-A ST Co., Ltd., Annual General Meeting, Mar 26, 2024

Dong-A ST Co., Ltd., Annual General Meeting, Mar 26, 2024

Price target increased by 7.6% to ₩77,624

Now 22% overvalued after recent price rise

Dong-A ST Co., Ltd. to Report Fiscal Year 2023 Results on Feb 15, 2024

FDA Accepts for Review BLA for DMB-3115 of Dong-A ST, a Proposed Biosimilar to Stelara

Upcoming dividend of ₩686 per share at 1.1% yield

New minor risk - Profit margin trend

Investor sentiment improves as stock rises 21%

New minor risk - Share price stability

Investor sentiment improves as stock rises 28%

Dong-A ST Co., Ltd. to Report Q2, 2023 Results on Jul 27, 2023

Now 21% undervalued after recent price drop

EMA Accepts MAA for DMB-3115 of Dong-A ST, a Stelara Biosimilar

Full year 2022 earnings released: EPS: ₩1,606 (vs ₩1,519 in FY 2021)

Dong-A ST Co., Ltd. Demonstrates Therapeutic Equivalence Between DMB-3115 and Stelara in Global Phase III

Upcoming dividend of ₩1,000 per share

High number of new directors

Price target decreased to ₩77,200

Price target decreased to ₩95,667

Less than half of directors are independent

Less than half of directors are independent

Upcoming dividend of ₩1,000 per share

Price target decreased to ₩105,000

Does Dong-A ST (KRX:170900) Have A Healthy Balance Sheet?

Dong-A ST's (KRX:170900) Problems Go Beyond Weak Profit

Full year 2020 earnings released: EPS ₩3,212 (vs ₩8,404 in FY 2019)

A Look At The Fair Value Of Dong-A ST Co., Ltd. (KRX:170900)

Dong-A ST Co., Ltd., Annual General Meeting, Mar 24, 2021

New 90-day low: ₩82,100

A Look At Dong-A ST's (KRX:170900) Share Price Returns

Is Dong-A ST Co., Ltd.'s (KRX:170900) Stock's Recent Performance A Reflection Of Its Financial Health?

Dong-A ST Co., Ltd. Completes the Proof-Of-Concept Study for ‘DA-1241,’ an Investigational First-In-Class Small Molecule with Mechanism of GPR119 Agonist Under Clinical Development, in Patients with Type 2 Diabetes

Dong-A ST Co., Ltd. to Report Fiscal Year 2020 Results on Feb 03, 2021

New 90-day low: ₩82,500

Is Dong-A ST Co., Ltd. (KRX:170900) Popular Amongst Institutions?

Is Dong-A ST Co., Ltd. (KRX:170900) A Good Fit For Your Dividend Portfolio?

Be Sure To Check Out Dong-A ST Co., Ltd. (KRX:170900) Before It Goes Ex-Dividend

Dong-A ST (KRX:170900) Has A Rock Solid Balance Sheet

Upcoming Dividend of ₩1,000 Per Share

New 90-day low: ₩83,800

Calculating The Intrinsic Value Of Dong-A ST Co., Ltd. (KRX:170900)

A Look At Dong-A ST's (KRX:170900) Share Price Returns

New 90-day low: ₩85,000

New 90-day high - ₩104,500

Dong-A ST Co., Ltd. to Report First Half, 2020 Results on Jul 29, 2020

Gewinn- und Umsatzwachstumsprognosen

Analystenprognosen zum zukünftigen Wachstum

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Wachstumsunternehmen entdecken